[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-459967-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-459967-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","differences-in-clinical-outcomes-among-patients-with-mold-fungemia-brief-report","Differences in Clinical Outcomes Among Patients With Mold Fungemia - Brief Report","","Mold bloodstream infections are rare but highly fatal, especially when caused by Lomentospora prolificans and Scedosporium species. Among 84 episodes spanning 20 years, the 30-day mortality rate reached 38%. Cancer, intensive care unit admission, and healthcare-onset infection were associated with higher mortality, emphasizing the need for early detection and improved management. The report presents a population-based analysis in Queensland, describing clinical features, microbiological spectrum, antifungal susceptibility patterns, and mortality risk factors.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/differences-in-clinical-outcomes-among-patients-with-mold-fungemia-brief-report/459967/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/differences-in-clinical-outcomes-among-patients-with-mold-fungemia-brief-report/459967.png","ImageObject",300,407,{"name":42,"@type":43},"McGucket","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":26},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What is the mortality rate for mold fungemia in this 20-year cohort?","Question",{"text":62,"@type":63},"The 30-day mortality rate was 38% across 84 episodes over 20 years.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"Which patient or care factors were linked to higher mortality?",{"text":67,"@type":63},"Cancer, intensive care unit admission, and healthcare-onset infection were associated with increased mortality rates.",{"name":69,"@type":60,"acceptedAnswer":70},"How were patients selected and what organisms were included?",{"text":71,"@type":63},"Patients receiving care in Queensland public hospitals (n=70) from 1 Jan 2000 to 31 Dec 2019 were included if mold or filamentous fungi were isolated from blood cultures.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},459967,1790757374,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":26,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":33,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":79,"read_time":123,"preview_page_count":4},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Open Forum Infectious Diseases  \nBRIEF REPORT  \nDifferences in Clinical Outcomes  \nAmong Patients With Mold Fungemia  \nAdam G. Stewart,1,2,3, Kevin B. Laupland,4,5 Felicity Edwards,4,5 Sharon C.-A. Chen,6,7,8, and Monica A. Slavin9,10,11,  \n1Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Boston, Massachusetts, USA, 2Harvard Medical School, Boston, Massachusetts, USA, 3Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Royal Brisbane and Women’s Hospital Campus, Brisbane, Queensland, Australia, 4Department of Intensive Care Services, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia, 5Queensland University of Technology, Brisbane, Queensland, Australia, 6Sydney Infectious Diseases Institute, The University of Sydney, Sydney, New South Wales, Australia, 7Department of Infectious Diseases, Westmead Hospital, Sydney, New South Wales, Australia, 8Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia, 9National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, New South Wales, Australia, 10Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, and 11Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia  \n\n| Mold bloodstream infections are rare but highly fatal, especially with Lomentospora prolificans and Scedosporium spp. Among 84 episodes over 20 years, the 30-day mortality rate was 38% . Cancer, intensive care unit admission, and healthcare-onset infection were linked to increased mortality rates, highlighting the need for early detection and better management strategies.\u003Cbr>Keywords. antifungal resistance; bloodstream infection; mold; mortality. |\n| --- |\n| Mold bloodstream infections (BSIs) are rare but lifethreatening conditions associated with significant morbidity and mortality rates, particularly in immunocompromised patients, such as those with hematological cancer, organ transplant recipients, or patients receiving immunosuppressive therapy [ 1, 2] . Mold fungemia is often due to Fusarium spp, Lomentospora prolificans, Scedosporium spp, and, less frequently, Aspergillus spp or other filamentous fungi [3, 4] . These infections pose significant diagnostic and therapeutic challenges due |\n\nReceived 23 June 2025; accepted 03 December 2025; published online 26 December 2025  \nCorrespondence: Adam G. Stewart, MD, PhD, Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 ([agstewart@mgh.harvard.edu](agstewart@mgh.harvard.edu)); Kevin B. Laupland, MD, PhD, Department of Intensive Care Services, Royal Brisbane and Women’s Hospital, Butterfield St, Brisbane, Herston, Queensland 4006, Australia ([kevin.laupland@qut.edu.au](kevin.laupland@qut.edu.au)) .  \nOpen Forum Infectious Diseases®  \n© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence ([https://creativecommons](https://creativecommons). org/licenses/by-nc-nd/4 .0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in anyway, and that the work is properly cited. For commercial re-use, please contact reprints@oup.-com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [journals.permissions@oup.com](journals.permissions@oup.com).  \n[https://doi.org/10.1093/ofid/ofaf793](https://doi.org/10.1093/ofid/ofaf793) ","cbCaiogmULrzoJcT","https://ap.wps.com/l/cbCaiogmULrzoJcT","pdf",330412,"English","# Brief Report\n## Differences in Clinical Outcomes Among Patients With Mold Fungemia\n## Methods\n## Mortality and Risk Factors","[{\"question\":\"What is the mortality rate for mold fungemia in this 20-year cohort?\",\"answer\":\"The 30-day mortality rate was 38% across 84 episodes over 20 years.\"},{\"question\":\"Which patient or care factors were linked to higher mortality?\",\"answer\":\"Cancer, intensive care unit admission, and healthcare-onset infection were associated with increased mortality rates.\"},{\"question\":\"How were patients selected and what organisms were included?\",\"answer\":\"Patients receiving care in Queensland public hospitals (n=70) from 1 Jan 2000 to 31 Dec 2019 were included if mold or filamentous fungi were isolated from blood cultures.\"}]","Differences in Clinical Outcomes Among Patients With Mold Fungemia - Brief Report | PDF"]